British Journal of Cancer · 1999 · 23 citations · 37 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyChemotherapyOncology PharmacotherapyAdverse Effects Of ChemotherapyAntiemetic TherapyChemotherapy Toxicity ManagementCombination ChemotherapyAcute Chemotherapy-induced NauseaAnti-emetic ProphylaxisChemotherapy-induced Nausea PreventionChemotherapy-induced Vomiting PreventionModerate-emetogenic Chemotherapy ProphylaxisOral TreatmentParallel Study DesignsPrednisolone Use
This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D2 antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223 women were enrolled and 218 patients (97.8%) were evaluable for efficacy. Granisetron (n = 109) was superior to prednisolone plus metopimazine (n = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (P < 0.001) and prednisolone plus metopimazine was superior on days 2-5 (P = 0.002). Overall, granisetron was superior on days 1-5 (P = 0.009). The median number of cycles completed with granisetron was five (95% confidence interval 4-6) compared with two (95% confidence interval 2-2) for prednisolone plus metopimazine (P = 0.0019). Constipation and rash were reported more frequently with granisetron (P < 0.001 and P = 0.043 respectively) and palpitations more frequently with prednisolone plus metopimazine (P = 0.015). In conclusion, the number of cycles completed with granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both treatments declined during multiple cycles of moderately emetogenic chemotherapy.
37
WHO Handbook for Reporting Results of Cancer Treatment
M K Palmer · British Journal of Cancer · 1982 · 2.2K citations · Full text
Medicine, Oncology, Cancer Control +11
Mark G. Kris, Richard J. Gralla, Leslie B. Tyson et al. · Journal of Clinical Oncology · 1989 · 240 citations